WuXi upgrades CAR-T offerings with new manufacturing platform by Carly Helfand Thursday, May 21, 2020 So far, manufacturing has been a hurdle for drugmakers in the burgeoning CAR-T field—but WuXi AppTec is doing its best to change that.
BMS, bluebird bio scramble after FDA rebuffs CAR-T submission by Kyle Blankenship Wednesday, May 13, 2020 The FDA cited manufacturing problems in refusing to review Bristol Myers' submission for a CAR-T cell therapy developed with bluebird.
Univercells' CDMO Exothera targets COVID-19 vaccine partners by Kyle Blankenship Thursday, March 19, 2020 Univercells's new CDMO, Exothera, is hoping to play a role in helping drugmakers scale up manufacturing for a possible COVID-19 vaccine.
Catalent laying out $315M to snatch another gene therapy CDMO by Eric Palmer Monday, February 3, 2020 Catalent, which carved out a place in gene therapies with its $1.2 billion Paragon Services deal, is now buying Masthercell Global for $315 million.
Real estate group creating gene therapy CDMO at former GSK site by Eric Palmer Thursday, January 23, 2020 The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.
Hospital jumping into production of gene therapies by Eric Palmer Tuesday, January 14, 2020 A new commercial-scale gene therapy manufacturing facility is being planned, but not by a biotech or a CDMO. This one will be built by a hospital.
Gene and cell therapy will kick into high gear in 2020 by Arlene Weintraub Thursday, December 19, 2019 Gene and cell therapies will make strides in 2020, but their developers will have to address challenges in manufacturing, reimbursement and more.
Lonza leader Marc Funk quits after just 9 months as CEO by Eric Palmer Tuesday, November 12, 2019 Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job.
Manufacturers get clarity and value with a distribution partner by Rebecca Willumson, In Partnership With AmerisourceBergen Friday, November 15, 2019 The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.
Bio-Techne investing up to $50M recombinant protein production by Eric Palmer Tuesday, October 29, 2019 With drugmakers focused on gene therapies, recombinant proteins supplier Bio-Techne says it will build a new plant to boost capacity.
